Hardman Research: Ready to press the button

Hardman Research: Ready to press the button

Ready to press the button:Diurnal is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building a long-term 'Adrenal Franchise'. Following successful completion of a Phase III trial, Infacort has been submitted to the European regulator for final approval. Meanwhile, management is establishing the appropriate commercial infrastructure in readiness for launch of Infacort and Chronocort in 2018 and 2020, respectively. Diurnal is also in the process of expanding its portfolio of products in the endocrine area.

Please click here for the full report:

http://www.hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/14.09.17-ready-to-press-the-button.pdf

To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH

Analysts: Dr Martin Hall [e-mail] Dr Dorothea Hill [e-mail] Dr Gregoire Pave [e-mail] Telephone:[phone] Follow us on Twitter@HardmanandCo

www.hardmanandco.com

About Hardman & Co:For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.